When it rains, it pours. BioMarin Pharma was not the only company to receive a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA). Gilead Sciences Inc. (NASDAQ: GILD) and Galapagos N.V. (NASDAQ: GLPG) were victims on Wednesday after the agency came down on their rheumatoid arthritis (RA) treatment.
Specifically, the CRL is for the New Drug Application (NDA) for filgotinib, an investigational treatment for moderately to severely active RA.
The FDA has requested data from the MANTA and MANTA-RAy studies before completing its review of the NDA. The FDA also has expressed concerns regarding the overall benefit/risk profile of the filgotinib 200 mg dose.
The MANTA and MANTA-RAy studies are fully recruited, with topline results expected in the first half of 2021. Filgotinib is currently under review by regulatory authorities around the world.
Also, filgotinib recently received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use, recommending marketing authorization for filgotinib in the European Union for the treatment of adults with moderate to severe RA who have responded inadequately or are intolerant of one or more disease-modifying anti-rheumatic drugs.
Management at Gilead noted that it continues to believe in the benefit/risk profile of filgotinib in RA, which has been demonstrated in the FINCH Phase 3 clinical program
Gilead stock traded down about 3% to $67.16 Wednesday morning, in a 52-week range of $60.89 to $85.97. The consensus price target is $80.17.
Galapagos stock was down 25%, at $140.80 in a 52-week range of $112.00 to $274.03. Analysts have a consensus price target of $224.31.
24/7 Wall St.Get Ready To Retire (Sponsored)
Start by taking a quick retirement quiz from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes, or less.
Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.
Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future
Get started right here.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
